| EPB144 | Association of age at ART initiation with CD4:CD8 ratio recovery among virally suppressed people living with HIV, 2001-2019 | E-poster | Other issues related to aging with HIV |
| EPB145 | Prevalence and Associated Factors of Healthy Aging with HIV in Latin America | E-poster | Other issues related to aging with HIV |
| EPB146 | Cost-effective continuous flow synthesis of HIV second and third generation integrase inhibitor drugs: a step towards local API manufacturing in Africa | E-poster | ART in acute, first- and second-line therapies |
| EPB147 | Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the 'real-world outcomes with dolutegravir-based two-drug-regimens for the treatment of HIV-1' (TANDEM study) | E-poster | ART in acute, first- and second-line therapies |
| EPB148 | Advanced HIV infection in the US: immune response to ART initiation | E-poster | ART in acute, first- and second-line therapies |
| EPB149 | Higher CD4/CD8 ratio recovery observed among people living with HIV started with integrase strand transfer inhibitors | E-poster | ART in acute, first- and second-line therapies |
| EPB150 | Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-up | E-poster | ART in acute, first- and second-line therapies |
| EPB151 | A pilot study of the impact of a rapid ART initiation in advanced HIV disease | E-poster | ART in acute, first- and second-line therapies |
| EPB152 | Country of birth influences INSTI prescription in treatment-naive patients living with HIV in France | E-poster | ART in acute, first- and second-line therapies |
| EPB153 | Starting antiretroviral therapy (ART) at the first HIV-specialist appointment with or without baseline laboratory data with BIC/FTC/TAF (The BIFAST study) | E-poster | ART in acute, first- and second-line therapies |